Featured Research

from universities, journals, and other organizations

Use of placebo in rheumatoid arthritis clinical trials may negatively impact patients, study suggests

Date:
May 27, 2011
Source:
European League Against Rheumatism
Summary:
Current study designs, assessing the effectiveness of new drugs for the treatment of rheumatoid arthritis (RA), discriminate against patients in the placebo-group, according to a critical appraisal assessing 17 trials. The authors of the study hypothesize that an active comparator group (i.e. current standard of care) should be used in all future new drug study designs as using placebo groups is not ethically acceptable.

Current study designs, assessing the effectiveness of new drugs for the treatment of rheumatoid arthritis (RA), discriminate against patients in the placebo-group, according to a critical appraisal assessing 17 trials, presented at the EULAR 2011 Annual Congress. The authors of the study hypothesize that an active comparator group (i.e. current standard of care) should be used in all future new drug study designs as using placebo groups is not ethically acceptable.

The results of this study, conducted in Germany, re-open the debate on whether it is ethical to conduct placebo-controlled studies where patients in the placebo-group are at a serious disadvantage compared to patients taking the new treatments. The study analysed current study designs, for new therapies such as abatacept (Orencia®), golimumab (Simponi®) or tocilizumab (Actemra®), and showed that patients in the placebo group experienced no change in medication, having to continue with their former, ineffective treatment plus placebo.

"According to the Helsinki-Declaration of the World Medical Association*, a placebo-controlled study design is deemed to be ethically acceptable when there is no other effective treatment," said Dr. Juche, Johanniter-Hospital, Treuenbrietzen, Germany. "However, this analysis confirms that patients in the placebo-group are at a disadvantage as they are given no change in medication to reduce their active inflammatory condition or halt disease progression. Our recommendation is that future clinical trials should include an active comparator group to ensure that all patients receive effective treatments to improve their quality of life."

In the analysis, researchers used studies from the European Public Assessment Report (EPAR) of the European Medicines Agency (EMA) for abatacept, golimumab and tocilizumab as samples. The studies chosen had to be placebo controlled at the beginning and state clinical relevant outcome criteria (e.g. DAS28**, ACR20***, Health Assessment Questionnaire and joint erosion scores).

Notes:

*The World Medical Association (WMA) is an organisation promoting the highest possible standards of medical ethics. The WMA provides ethical guidance to physicians through its Declarations, Resolutions and Statements.

**DAS28 (Disease Activity Score) is an index used by physicians to measure how active an individual's RA is.

***ACR (American College of Rheumatology) criteria measures improvement in tender or swollen joint counts.


Story Source:

The above story is based on materials provided by European League Against Rheumatism. Note: Materials may be edited for content and length.


Cite This Page:

European League Against Rheumatism. "Use of placebo in rheumatoid arthritis clinical trials may negatively impact patients, study suggests." ScienceDaily. ScienceDaily, 27 May 2011. <www.sciencedaily.com/releases/2011/05/110527075909.htm>.
European League Against Rheumatism. (2011, May 27). Use of placebo in rheumatoid arthritis clinical trials may negatively impact patients, study suggests. ScienceDaily. Retrieved September 2, 2014 from www.sciencedaily.com/releases/2011/05/110527075909.htm
European League Against Rheumatism. "Use of placebo in rheumatoid arthritis clinical trials may negatively impact patients, study suggests." ScienceDaily. www.sciencedaily.com/releases/2011/05/110527075909.htm (accessed September 2, 2014).

Share This




More Health & Medicine News

Tuesday, September 2, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

Newsy (Sep. 2, 2014) — The U.N. says the problem is two-fold — quarantine zones and travel restrictions are limiting the movement of both people and food. Video provided by Newsy
Powered by NewsLook.com
Get on Your Bike! London Cycling Popularity Soars Despite Danger

Get on Your Bike! London Cycling Popularity Soars Despite Danger

AFP (Sep. 1, 2014) — Wedged between buses, lorries and cars, cycling in London isn't for the faint hearted. Nevertheless the number of people choosing to bike in the British capital has doubled over the past 15 years. Duration: 02:27 Video provided by AFP
Powered by NewsLook.com
Can You Train Your Brain To Eat Healthy?

Can You Train Your Brain To Eat Healthy?

Newsy (Sep. 1, 2014) — New research says if you condition yourself to eat healthy foods, eventually you'll crave them instead of junk food. Video provided by Newsy
Powered by NewsLook.com
We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) — A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins